Defining the microglia response during the time course of chronic neurodegeneration

Running title: Microglia in neurodegeneration

James E. Vincenti, Lita Murphy, Kathleen Grabert, Barry W. McColl, Enrico Cancellotti, Tom C. Freeman ± and Jean C. Manson* ±

The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Easter Bush, Midlothian EH25 9RG, United Kingdom

± Joint senior authors

Corresponding author:

*Professor Jean Manson: jean.manson@roslin.ed.ac.uk

Conflict of Interests
None of the authors have any conflict of interest relating to this study

Authors Contributions
JV, EC, TF and JM designed the study, JV conducted the research, JV, TF and JM analysed the data, JV, TF and JM wrote the manuscript. BM, KR, LM provided tools and expertise and provided a valuable review of the manuscript.

36 pages, 9 figures, 1 supplementary table
Abstract 248 words, Text 5470
Abstract

Inflammation has been proposed as a major component of neurodegenerative diseases although the precise role it plays has yet to be defined. We have examined the role of key contributors to this inflammatory process, microglia, the major resident immune cell population of the brain, in a prion disease model of chronic neurodegeneration. Initially, we performed an extensive reanalysis of a large study of prion disease, where the transcriptome of mouse brains had been monitored throughout the time-course of disease. Our analysis has provided a detailed classification of the disease-associated genes based on cell type of origin and gene function. This revealed that the genes up-regulated during disease, regardless of the strain of mouse or prion protein, are expressed predominately by activated microglia. In order to study the microglia contribution more specifically we established a mouse model of prion disease in which the 79A murine prion strain was introduced by an intraperitoneal route into BALB/c\textsuperscript{fms-EGFP/-} mice, which express Enhanced Green Fluorescent Protein (EGFP) under control of the \textit{c-fms} operon. Samples were taken at time points during disease progression and histological analysis of the brain and transcriptional analysis of isolated microglia was carried out. The analysis of isolated microglia revealed a disease specific, highly pro-inflammatory signature in addition to an up-regulation of genes associated with metabolism and respiratory stress. This study strongly supports the growing recognition of the importance of microglia within the prion disease process and identifies the nature of the response through gene expression analysis of isolated microglia.
Importance

Inflammation has been proposed as a major component of neurodegenerative diseases. We have examined the role of key contributors to this inflammatory process, microglia, the major resident immune cell population of the brain, in a murine prion disease model of chronic neurodegeneration. Our study demonstrates that genes up-regulated throughout the disease process, are expressed predominately by microglia. A disease specific highly pro-inflammatory signature was observed in addition to an up-regulation of genes associated with metabolism and respiratory stress. This study strongly supports the growing recognition of the important contribution of microglia to a chronic neurodegenerative disease process.

Key Words

Microglia, Neurodegeneration, Prion

Introduction

Over several decades the neuron has been subject to the majority of research into protein misfolding diseases, but it is now apparent that glial cells are important players in the neurodegenerative process. Many protein misfolding diseases including Alzheimer’s disease, Parkinson’s disease and prion diseases demonstrate activation of glial cells in the brain during the course of disease alongside accumulation of misfolded protein but the precise role of the glial cells in the disease process is not known (1-4). Transmission of prion agents
to mice provides an excellent model for studying the timing of events during a chronic process of a neurodegeneration associated with a misfolded protein. The time of inoculation defines the starting point for the disease process and highly reproducible characteristics of mouse-adapted prions include accumulation of a misfolded host protein, gliosis, neuronal loss, distribution of brain lesions and the end point of terminal disease. Activation of glial cells, both astrocytes and microglia, has been extensively documented as an early event in the pathogenesis of protein misfolding diseases, occurring well before the onset of clinical disease (1, 5-7).

Microglia are the major resident immune cell in the brain and in steady-state are considered a heterogeneous population with density differences across brain regions (8). They display region dependant functional signatures, which are enhanced further by age (9). Under normal conditions microglia adopt a ‘resting’ phenotype where they continually survey their immediate environment with extended processes (10).

Following detection of a pathological insult or any disturbance to homeostasis, microglia adapt their phenotype from ‘resting’ to ‘activated’ whereby they modify both morphology and biological function (10-12). Activated microglia have diverse functional phenotypes dependent on the nature of the stimuli that are not readily apparent from their morphology, and include a much wider repertoire than the classically defined M1 and M2 phenotypes (13-16). It has also been proposed that microglia can readily switch from one phenotype to another (17-19) and are sensitive to peripheral immune system communication (20-22). It is also clear that a complicated interconnected network of CNS
cells contribute to the activated ‘profile’ adopted by microglia with signalling from both astrocytes and neurons having particular impact (23-26).

The change of microglia from a resting to an activated state is one of the first pathological features of prion disease long before there is any evidence of neurodegeneration. Activated microglia are widely distributed in the brain and are thought to express low levels of inflammatory cytokines but high levels of transforming growth factor beta 1 (TGFβ1) and prostaglandin E2 (PGE2) (7, 27).

This study aims to investigate the role of microglia through detailed analysis of their morphology and gene expression during the course of prion disease thereby providing new insights into the pathophysiology of neurodegenerative disease. We have used a prion disease agent as a model of neurodegeneration and taken an unbiased whole genome expression analysis approach, which has allowed us to provide an insight into the molecular processes central to microglia during the neurodegeneration, and highlight how this may impact disease development. A strong myeloid association was attributed to disease associated genes identified in our reanalysis supporting the growing recognition of the importance of microglia within the disease process. To further clarify microglial contribution we isolated microglia from prion infected mice and analysed their gene expression profile.
Material and methods

Reanalysis of Hwang et al. (2009) Data

The Hwang dataset (28) was downloaded from http://prion.systemsbiology.net. Quality control of these data was performed by Fios Genomics Ltd. (Edinburgh, Scotland) using the ArrayQualityMetrics (29) and 32 microarrays were removed due to poor quality leaving 386, both infected and uninfected, for reanalysis. The removal of arrays did not affect the overall balance of the dataset with a mean average of 2.5 ± 0.08 SE arrays per time point. Data normalisation was performed using the Robust Multiarray Average (RMA) expression measure (30).

Initial inspection of the data showed that there were no age-related trends present in the control animal data and these were not included in further analyses. Data from prion infected animals were loaded into BioLayout Express³D (31) and a Pearson correlation matrix calculated, comparing the expression data from each probeset on the array against all other probesets ($P^2/2$ pairwise calculations, where $P$ is the number of probesets).

A threshold of $r \geq 0.75$ was used and the resultant correlation graph visualised. To identify groups of co-expressed genes, the graph was clustered using the graph-based Markov clustering (MCL) algorithm (32) with the inflation value set at 2.2. The expression profile of each cluster was inspected, and clusters of genes differentially expressed during disease were isolated and individual gene profiles examined. Those with an unconvincing profile, i.e. their expression was weak or unrelated to disease progression, were removed. This left a
Determination of Cell Type of Origin and Function of Disease-associated Transcripts

Cell origin was determined with reference to existing datasets. A dataset was compiled from data derived from a number of published studies and included microglia, macrophage and osteoclast myeloid populations (33, 34); purified neuronal populations derived from the cortex (cholecystokinin\(^+\), cholinergic, layer 5a, layer 5b, layer 6, prepronociceptin\(^+\)); the striatum (dopamine receptor subtype-1 medium spiny, dopamine receptor subtype-2 medium spiny) and the cerebellum (basket, Golgi, purkinje, stellate, unipolar brush) and astrocytes, Bergman glia and oligodendrocyte populations (35, 36). Finally, datasets derived from macrophage cultures cultured with lipopolysaccharide (LPS) bacterial endotoxin (37) were included to allow for the identification of those genes associated with activation of the innate immune system. Following normalisation of the data, the 492 genes demonstrating differential expression in response to prion disease were identified in the composite dataset through matching of gene symbols, and incorporated into an expression file. Within BioLayout Express\(^{3D}\) each gene could then be assessed for their expression in one or more of these cell types.

Gene ontology enrichment was determined by uploading the Affymetrix chip ID of the disease-associated genes to the online Ensembl Biomart data mining tool (ensembl.org/biomart) using the Mus musculus genes dataset (Ensembl Genes 66). Filters were applied restricting results to the Affymetrix 430 2.0 chip probe sets. To increase
accuracy for correct selection of function, filters for gene ontology evidence code, domain and name were applied, with experimental evidence codes preferred.

Animals and Treatment

Groups of male and female BALB/c\textsuperscript{fms-EGFP/-} mice, expressing enhanced green fluorescent protein (EGFP) under control of the c-fms operon (part of the Csfr1 promoter) (38), were sex matched and housed under standard conditions in groups of three to five. Food and water access was \textit{ad libitum}. All mouse experiments were reviewed and approved by the local ethical review committee and performed under license from the UK Home Office in accordance with the United Kingdom Animal (Scientific Procedures) Act 1988. Mice aged at 16 weeks old were challenged by an intraperitoneal (i.p.) route with 0.02 ml of 1\% w/v (in physiological saline) 79A infected or normal brain material (NBr) for control. At time points 35, 100, 150 and 200 days post-inoculation (dpi) mice were sacrificed (9 per group for immunohistochemical analysis and 4 per group for microglial extraction). All remaining mice (12 and 8 per group respectively), were assessed for clinical signs of prion disease from 150 dpi, and incubation times were calculated according to previously described protocols (39). These mice were sacrificed during terminal disease, or earlier if welfare required.

Tissue sections from these mice were assessed for spongiform degeneration following previously described procedures by a scientist blinded to experimental design (40).

Tissue Preparation and Immunohistochemical Analysis

Brains were removed at the selected time points. Those to be used for immunohistochemistry were perfusion fixed with saline followed by 4\% paraformaldehyde
Brain tissue was embedded in paraffin and cut into sections (6 μm). Antigen retrieval was performed in an autoclave at 121°C for 15 min in dH2O and then incubated in formic acid (98%) for 10 min at room temperature. Endogenous peroxidase was blocked with 1% H2O2 (Sigma-Aldrich) in methanol for 10 min. All sections were blocked with serum-free protein block (Dako) or normal goat serum prior to incubation with the primary antibody. Sections were immunostained with monoclonal antibody (MAb) 6H4 (Prionics) recognizing residues 143-151 of murine PrP (0.5 μg ml⁻¹) (41). Negative control slides were treated overnight with mouse immunoglobulin control (Invitrogen). Antibody binding was detected with Vector ABC kit (Vector laboratories) and visualized with 3,3-diaminobenzidine chromogen. All sections were counterstained with haematoxylin.

Brains for microglia morphology assessment were removed and immersed in 4% PFA for 24 h, rinsed in Hank’s balanced salt solution (HBSS) before incubating for a further 24 h in 20% sucrose solution at 4°C. Tissues were rinsed with HBSS and snap frozen in isopentane at -40°C. Brains for microglial extraction were immersed in cold HBSS prior to processing (see microglial isolation procedure).

**Quantification of Microglia Morphology/ Phenotype**

Frozen brain tissue was sectioned at 25 μm on a freezing block microtome and sequential sections 300 μm apart were taken for analysis. Quantification of microglia activation status was established on cellular aggregation and morphology observed in BALBc<sup>Fms-EGFP</sup> sections based on the average number of microglia per 0.05 mm². Images for cell quantification were captured as a 50 optical slice z-stack at x10 magnification (Zeiss Plan-Neofluar 10x/0.30...
objective) and compiled into a composite image using ImageJ software 1.48a. Quantification of EGFP cell number was performed using particle analysis within ImageJ. Microglia radius was performed on x10 Z stack compiled (reporting Z stacks) images taken at x40 magnification (Zeiss Plan-Neofluar x40 / 1.30 objective) captured from three standard locations within four brain regions: the dentate gyrus, cerebellum, medulla and thalamus. There was a minimum of 3 mice per group and additional images were recorded on adjacent sections if the total number of EGFP expressing microglia was below 50. Euclidean distance mapping was utilised to quantify changes in morphology and was performed using the ‘region of interest’ function within ImageJ.

Microglial isolation procedure

Brains harvested for microglial extraction were placed in cold HBSS and diced before processing immediately. Brains were dissociated using a GentleMACS™ Dissociator (Miltenyi Biotec) and Neural Tissue Dissociation Kit P (Miltenyi Biotec). The final cell pellet was re-suspended in 16 ml 35% Isotonic Percoll, split between two 15 ml tubes and carefully overlaid with 5 ml ice cold 0.1% DEPC treated HBSS. The resulting Percoll gradient was centrifuged at 400 g for 45 min at 4°C. The pellets were then suspended and recombined into a final volume of 5 ml ice cold 0.1% DEPC treated HBSS. Cells were pelleted at 400 g for 5 min at 4°C using no brake, re-suspended in 90 µl ice cold MACs buffer (Miltenyi Biotec), 10 µl CD11b (microglia) microbeads (Miltenyi Biotec) and incubated at 4°C for 15 min with gentle rotation. Following incubation with microbeads, the cell suspension was washed in 1 ml ice cold MACs buffer at 300 g for 5 min at 4°C then re-suspended in 500 µl
ice cold MACs buffer. Cells were passed through magnetised LS columns (Miltenyi Biotec) following the manufacturer’s protocol.

**Verification of Microglial Purity**

A subset of isolated cells predicted to be microglia were stained with PE anti-mouse CD11b (Cambridge Bioscience) and APC anti-mouse CD45 (Cambridge Bioscience). Isotype controls were prepared using PE Rat IgG2b (Cambridge Bioscience) and APC Rat IgG2a (Cambridge Bioscience) and a subset of unstained cells served both as negative control and verification of correct BALB/cFms-EGFP/- genotype. Cell viability was determined using SYTOX® Blue dead cell stain (Thermofischer Scientific). All cell samples were analysed on a BD FACS Aria IIIu 4-laser/11 detector cell sorter running BD FACS Diva™ software (BD Biosciences). Subsequent analysis of FACS data was also performed using Summit v4.3 software (Dako/Beckham Coulter).

**Microarray Analysis of Isolated Microglia**

Isolated microglia cells were treated with TRIzol® Reagent (Life Technologies) according to manufacturer’s protocol. Total RNA quality was checked on an Agilent 2100 Bioanalyzer. RNA samples with RIN value of >7.0 were passed as suitable for analysis and two representative samples at each time-point for control and disease were taken forward for analysis. RNA processing was handled by Ark Genomics (The Roslin Institute & R(D)SVS). RNA was converted to amplified double-stranded cDNA containing biotin using the NuGen Ovation picoSL WTA labelling kit (NuGen). The cDNA samples were hybridised to Affymetrix...
Mouse Gene 1.1 arrays on a GeneTitan instrument (Affymetrix). Data was quality controlled, RNA normalised and subjected to network analysis as described above.

Results

The neurodegenerative disease process is associated with an inflammatory response which is microglial in origin

Initially, we performed a reanalysis of the data produced by Hwang et al. (2009): a transcriptomics analysis of brains of multiple strains of mice infected with different prion strains sampled at various stages of disease progression. These analyses were performed with a view to identifying genes associated with neurodegenerative disease progression. The Hwang data from diseased animals were analysed within BioLayout Express\textsuperscript{30}. A correlation graph was generated using a Pearson threshold of $r \geq 0.75$, consisting of 21,550 nodes with 1,253,332 edges (Figure 1A). Clustering with MCL yielded 416 clusters. Each cluster represented genes that share a high degree of co-expression. The expression profile of the majority of the clusters revealed they had an expression profile that was not linked to the disease process. Two major clusters of genes did however exhibit an expression profile that increased with disease progression in all animal/prion strain combinations (Figure 1B). The largest of these clusters comprised 377 genes and a second contained 115 genes that were notable for their increased activation in C57/Bl6 models (Figure 1B). Following manual inspection of all individual profiles, a total of 492 genes associated with prion disease development were identified (Supplementary Table 1). All genes in each cluster followed a similar expression profile with an increase in expression starting at approximately half way through the incubation period.
Once disease association was determined, we next attempted to identify the cellular origin for each of the 492 differentially expressed genes in question. This was done by examining the expression of the disease-associated genes in the context of a panel of isolated cell populations. Datasets were sourced from the GNFv3 cell atlas (33, 34), RNA TRAP (35, 36) and serial macrophage cultures subjected to LPS (37). This revealed that 315 out of the 492 differentially expressed genes were solely or at least predominately expressed by myeloid populations, thereby indicating the majority were likely expressed by microglia within the brain. In contrast, 147 of the genes were expressed by multiple cell types, whilst only 30 were found to be specific to astrocytes, oligodendrocytes and neurons collectively (Figure 2). The original study by Hwang et al., (2009) identified 333 differentially expressed genes. By overlaying these 333 genes onto our chosen external datasets within BioLayout Express 3D it was found that 158 of the 333 genes were attributed to a myeloid origin. A further 18 were attributed to non-myeloid cell types. The remaining genes were classed as generic, implying the origin could be any cell within the brain and as such do not rule out a microglial component.

**Histological Analysis of Microglial Activation and PrP Deposition**

Following the identification of the predominantly myeloid origin of the prion disease signature, we chose next to confirm this observation by performing an analysis of microglia isolated from diseased brains. Our aim was to verify these findings and to obtain a more detailed analysis of the activation of microglia during disease. To do this we chose a mouse
passaged prion agent 79A, inoculated into BALB/cJ Fms-EGFP/- mice by an intraperitoneal route with 0.02 ml of 1% w/v 79A brain homogenate as our model.

Clinical disease onset occurred 198.5 +/- 1.0 (SEM) dpi with signs including lethargy, hair unkempt/loss and hunching all reported. Terminal disease occurred 229 +/- 3.6 dpi. Pathological analysis of the vacuolation in the brain of terminal animals (n=6) confirmed clinical disease and indicated that vacuolation was widespread by terminal stage of disease presenting as typical for the 79A prion strain (42, 43).

PrP deposition assessed by immunohistochemistry using the 6H4 antibody was first detected in the infected mice at 150 dpi and restricted to the medulla (Figure 3A/B). PrP assessment at the terminal stage of disease identified heavy accumulation of fine punctate particles throughout the majority of the brain, strongest in the thalamus and extending into the medulla. To a lesser extent, deposition was also observed within the hippocampus, but it was only occasionally found within the cortex. This is the deposition pattern typically associated with 79A disease progression (42, 44). Microglial activation was observed in the same areas as PrP deposition at 150 dpi (Figure 3C/D). Microglia in the NBr inoculated controls demonstrated ramified appearance and greater microglia separation at ~50 µm (Figure 3E/F).

Microglia were identified during the course of disease using EGFP expression and a quantitative analysis performed on their density and radius, as a measurement of morphological changes typically associated with the activation of microglia. Comparison to animals that had been inoculated with uninfected NBr homogenate, we observed at 150 dpi
an approximate 50% ($p = 0.029$) increase of microglial cell number per 0.05 mm$^2$, within the medulla of 79A infected mice (Figure 4A). Similarly, at 200 dpi an increase of microglia of approximately 50% ($p = 0.02$) was observed within the thalamus. The intercellular distance of microglial in control and unaffected regions was approximately 70-100 µm, while within affected regions this was reduced to approximately 25 µm (Figure 4B). Cellular microglial activation was also defined by a marked increase in the diameter of the central body while there is a reduction in the length and number of processes projecting from it (45). An average length of approximately 30 µm was observed for thalamic microglia at 100 days, while at 200 dpi this is reduced to an average of 20 µm, indicating morphology associated with activation. The reduction in radius is matched with an increase in Euclidean distance by 1 µm, similar to that seen in the microglia in the thalamus, and indicative of shorter thicker processes and a larger central body (Figure 4C-E). Thus the pathological analysis confirmed that microglial activation and PrP disease associated protein deposition occurs by 150 dpi in restricted regions of the brain, and during the course of disease both extend into multiple brain regions. There was no evidence of either PrP deposition or microglial activation at 100 days in this model.

**Microglial activation profile**

Microglia were isolated at day 35, 100, 150 and 200 dpi from 79A inoculated and control animals. Isolated cells were stained with CD11b and CD45 fluorochrome conjugated antibodies and sorted by FACS to confirm purity (Figure 5A-D). Adult microglia are typically shown as CD11b$^{High}$ and CD45$^{Low}$ (46) and the lower than expected CD11b forward and side scatter may be attributed to competition for available antigen between the CD11b
microbeads and CD11b-PE marker. The number of CD45\textsuperscript{high} cells, indicative of impurities in the cell isolation process by monocyte contamination, was negligible. Non-specific binding or auto-fluorescence was not observed. Cell viability was confirmed as 97% ± 0.43 SE. Microglia purity was further confirmed from the expression profile of twenty cell-specific genes representing the main cell groups found within the brain (Figure 5E). The presence of CD11b\textsuperscript{positive} circulating or inflammatory monocytes was confirmed to be absent as evidenced by the negligible expression of Ly6c or Ccr2 (Supplementary Figure 1).

The process of isolation did not appear to adversely affect the microglia disease signature. There was a clear difference between expression profiles of microglia isolated from diseased mice and those collected from uninfected controls. Of note was the lack of increased expression of metabolism genes that may be expected if cells were unduly stressed during the isolation process. Staining with SYTOX\textsuperscript{®} Blue also confirmed cells from both infected and control animals were viable prior to RNA isolation. Additionally, on a bright field microscope, isolated microglia presented with a rounded refractive appearance, indicative of healthy viable cells.

RNA was extracted and microarray analysis was performed. Following this, the patterns of gene expression were analysed within BioLayout Express\textsuperscript{3D}. The expression profile of each cluster was individually checked to ensure familiarity with the dataset, and those with a disease associated signature selected. This resulted in 741 genes that demonstrated an increase in expression predominately at 200 dpi. The 741 genes were also organised into 2 large clusters which shared a very similar gene expression profile with a clear increase in expression profile (shown averaged in Figure 6A). Animals inoculated with NBr material
showed no significant change in expression throughout the corresponding period. Using the 741 genes of interest, a sample-to-sample (array) level graph within BioLayout Express3D was generated and confirmed the arrays from the 200 dpi time point had less correlation with the rest of the samples (Figure 6B).

**Gene Enrichment Analysis**

Enrichment analysis of the disease-associated microglial genes using the FuncAssociate 2.0 database (47), confirmed the enrichment (p<0.001) of the following functional gene descriptions; translation, energy production, immune response, interferon response and cell stress (Figure 7A). Immunological response comprised the single largest category in respect to total gene number. The signature included transcripts associated with proteolysis, NFkB-mediated cytokine cascades and innate immunity. The GO enrichment functional groups of mitochondria, ribosome, cell stress, apoptotic process and proliferation confirmed the presence of a significant metabolic signature associated with these genes.

Gene ontology was performed for each gene using the data made available on the Ensembl Biomart database to allow for functional associations to be determined (Figure 7B). Just under two thirds of the 741 identified differentially expressed genes were attributed to metabolism and the maintenance of homeostasis. The correct determination of differentially expressed metabolic genes to a specific cell type is only possible through the type of isolated cell type analysis presented here. Metabolic genes are typically expressed by all tissue cells types, making identification of the cellular origin from a mixed cell population impossible. Genes that were related to the immune response comprised just...
under a quarter of the total. The 6% of genes associated with cytoskeletal changes and migration were classed into their own groups respectively and included genes associated with membrane reshuffling. This was to be expected as microglia are known to be highly motile in the healthy brain environment (10). The increased expression of cytokines IL1, TNFα and CSF1, but not IL6 or IL10, would suggest the response by microglia is lacking in the full spectrum of cytokines expected from a classical form of activation via the myeloid differentiation primary response 88 (MYD88)-dependant pathway (48). Pathway analysis of this dataset within the Reactome database (49), revealed many of the elements of the MYD88-independent pathway were represented by the differentially expressed genes within this study. This is supported by the lack of differential expression of MYD88 (Figure 7C). In addition, TGFβ1 was not found to be differentially expressed by microglia during the disease process (Figure 7D). Transcripts associated with TGFβ1 signalling, including Smad anchor for receptor activation (Zfyve9), suppressor-of-cytokine-signalling 3, 4 and 5 (Socs3-5) and ubiquitin specific peptidase 15 (Usp15) were also absent.

Determination of the sub-cellular component for each gene considered to be associated with metabolism/homeostasis was performed from data obtained from the Ensembl Biomart database. This enabled the location of many genes to be plotted onto a cellular map and further organised by function (Figure 8). The identified cellular components included a significant increase in expression of genes associated with ribosomes within the rough endoplasmic reticulum and cytoplasm. Indeed, the bulk of the metabolic genes were associated with the ribosomes, thereby implying an increase in ribosome numbers and/or ribosome turnover, or an increase in protein synthesis. Also present was a significant
concentration of genes associated with proteolysis, including proteasome based ubiquitination.

Consistent with the increase in metabolic load were a considerable number of genes associated with oxidative phosphorylation and energy production in mitochondria, including subunits for cytochrome-c oxidase, NADH dehydrogenase and lactate dehydrogenases; the latter associated with breakdown of increased levels of lactate in situations of respiratory stress (50). Also observed were DNA repair processes including expression of poly(ADP-ribosyl)ation-14 (Parp14); a potent transcriptional regulator and DNA damage-dependant nuclear protein (51, 52).

The association of the identified genes of interest with a specific function outside metabolism/homeostasis was plotted onto a cellular map using ontology data obtained from the Ensembl Biomart database. This enabled the location of each gene to be determined and further organised by function (Figure 9). The overall expression profile from this set of genes is one of robust pro-inflammatory myeloid cell activation. The increased expression of lysosomal-associated membrane protein, ATPase proton pumps and numerous lysosomal enzymes including cathepsins, histocompatibility subunits and genes involved in membrane restructuring, strongly support antigen presentation and are a hallmark of classically activated innate immune cells. Increased expression of surface marker transcripts Cd48, Cd86, Ccl8, Cxcl9, Cxcl13, and Tlr2 was also observed and all are typically associated with a pro-inflammatory classical activation phenotype (16, 53-55).
Discussion

The dataset generated by Hwang, et al. (28) is uniquely placed among transcriptome datasets as it is the first to be fully comprehensive in terms of prion-related disease models, encompassing as it does multiple prion strains and host backgrounds. Our reanalysis of these data using a correlation network-based approach in combination with a cell origin classification system has given a unique, unbiased and informative whole genome approach. This allows identification not only of a core set of genes involved, but also of cell types associated with the neurodegenerative disease process. We identified a further 299 disease-associated genes not reported in the original study by Hwang, et al. (28) (Table 1). The original analysis focused on defining pathways associated with disease progression, which speculated a prominent neuronal contribution to the disease signature. However our reanalysis identified a large proportion of those previously identified genes to be of a myeloid origin with a strong myeloid association being attributed to 315 out of the 492 disease associated genes. This supports the growing recognition of the importance of microglia within the disease process. To further clarify microglial contribution we isolated microglia from prion infected mice and analysed their gene expression profile.

Experimental differences between the current study and that of Hwang, et al. (28) including route of infection, single cell type analysis and RNA amplification, potentially limit the ability to directly compare the results of the two studies. Having said this 107 genes were seen to be upregulated during disease progression in both studies and were primarily associated with an innate immune response (Supplementary Figure 1). We adopted an intraperitoneal route of infection as a “more natural” route of infection rather than the more commonly
used intracranial route to ensure that microglial activation was the result of a response to initial infection entering the CNS environment. With an intracranial route of infection the microglial response may be complicated by the injection procedure resulting in what has been termed as ‘pre-priming’ of microglia (56-58). A peripheral route would also encapsulate any microglial response to systemic inflammation; observed in prion disease following a peripheral route of infection (59), but not following an intracerebral route (60).

However both studies arrive at the same conclusion; prion disease is associated with a chronic inflammatory response with microglia being central to the disease process.

The increase in levels of \(\text{Il1b}, \text{Tnfa}\) and \(\text{Csf1}\) strongly portray the microglial activation profile as pro-inflammatory and not one of atypical down-regulation or resolution of inflammation (61). The presence of a significant increase in transcripts involved with proteasome activity and major-histocompatibility mediated antigen presentation, combined with expression of \(\text{Cxcr3}\) ligand genes, offers a microglia activation state more akin to classically activated macrophages. That said, the lack of expression of \(\text{Infγ}, \text{Il6}\) and \(\text{Il33}\) by microglia, all well-defined pro-inflammatory cytokines (62-64) suggests an atypical inflammatory response. Also of note, and crucial to the maintenance of a chronic response to inflammatory cytokines, was that expression of \(\text{Nfkb1}\) remained stable despite an increase in expression of NFkB1 inhibitors (\(\text{Nfkbia}, \text{Nfkbib}\) and \(\text{Nfkbie}\)) which have been shown to inhibit formation of NFkB1 at the transcription stages (65).

The inflammatory phenotype typically associated with prion disease has been shown to be remarkably anti-inflammatory and dominated by the anti-inflammatory growth factor Tgf-\(\beta1\) following injection by an intracerebral (66) or hippocampal stereotactic route (7, 61).
Found in the healthy brain, Tgf-β1 is a constitutively expressed protein intricately involved in microglia homeostasis (67-70). The lack of differential expression of Tgfb1 within this dataset, suggests a lack of active TGF-β1 mediated signalling as a significant contributor to the disease response by microglia. There was also lack of significant increase in expression of Usp15, Zfyve9 or Socs3-5, indicating no increased translocation of SMAD2/3 proteins or MAPK signalling; core intracellular complexes of the TGF-β1 signalling pathway (67, 71-73).

TGF-β1 is required for the correct function of the blood brain barrier, and is itself unable to pass (74, 75). This therefore suggests that the increased expression of Tgf-β1 noted in other studies, is either attributable to the intracerebral inoculation or expressed by another group of cells from within the CNS.

Microglia are known to intricately interact with neurons (76-78), and numerous genes associated with axon elongation, synapse regulation and neurotransmitter release were observed to increase in expression within the isolated microglia dataset. This partners the expression of many axon and synapse genes with microglia and adds them to the growing body of evidence for microglial involvement in neuron regulation (79-83). It has been proposed that microglia kill prion infected neurons in a manner dependent upon the presence and degree of fibrillarity of misfolded protein (84). This single cell dataset supports the generation of a neurotoxic response from microglia with increased expression of Il1b, Tnfa and caspase-4 (Casp4) indicating active processing within caspase-1 mediated inflammasomes (85-87). Other pro-inflammatory genes found within this dataset, and reported to be neurotoxic, include matrix metalloproteinase 12 (Mmp12) (88) and prostaglandin-endoperoxide synthase 2 (Ptgs2) (89). The latter is known to be expressed in
prion disease (90, 91) and is a target of non-steroidal anti-inflammatory drugs (NSAIDs) used in clinical trials to treat neurodegenerative diseases by inhibiting prostaglandin synthesis (92).

Within this analysis microglia were shown to express a disease signature markedly more pro-inflammatory than that currently portrayed in the literature for prion disease, and more akin to other protein-misfolding diseases, notably Alzheimer’s disease, in which microglia are observed as expressing a repertoire of pro-inflammatory cytokines including Tnfa, Il1b and Il6 (93-95). The increased expression of cytokines Il1b, Tnfa and Csf1, but not Il6 in this dataset suggests an activation profile that is specific to prion disease and likely also unique to the in-vivo environment since co-cultures of microglia and neurons in the presence of PrP106-126 induces a stereotypic response with CD14 mediated detection of damaged neurons and increased expression of Il6 (96). This matches the stereotypic neurotoxic response observed in co-cultures of neurons in the presence of LPS activated microglia (97).

Our study demonstrated that genes up-regulated throughout the disease process, are expressed predominately by microglia. A disease specific highly pro-inflammatory signature was observed in addition to an up-regulation of genes associated with metabolism and respiratory stress. This study strongly supports the growing recognition of the important contribution of microglia to a chronic neurodegenerative disease process. Protein misfolding diseases typically have a very long pre-clinical phase in which there is a steady and progressive increase in misfolded protein deposition, neuroinflammation and synaptopathy as the disease progresses. Thus an understanding of the contributors to this pre-clinical
phase provides opportunities for devising early intervention strategies to limit the pathology before damage becomes irreversible.

Funding Information

This study was funded by DTA studentship from the BBSRC. The funders had no role in study design, data collection and interpretation.

Acknowledgements

We would like to acknowledge the extensive support and expertise of Mrs Aileen Boyle, Mrs Gillian McGregor, Ms Dawn Drummond and Mrs Sandra Mack for pathology services, Mrs Rebecca Hogan for animal care, Mr Bob Fleming and Dr Deborah Brown for assistance with bioimaging and to Ms Lynesay McKay for assistance with Miltenyi Biotec equipment.

GEO accession number: GSE72039

References


Murray CL, Skelly DT, Cunningham C. 2011. Exacerbation of CNS inflammation and neurodegeneration by systemic LPS treatment is independent of circulating IL-1beta and IL-6. Journal of neuroinflammation 8:50.


Dongen V. 2000. Performance criteria for graph clustering and Markov cluster experiments. CWI (Centre for Mathematics and Computer Science):


<table>
<thead>
<tr>
<th>Number</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>83</td>
<td>Sogn C, Puchades M, Gundersen V. 2013. Rare contacts between synapses and microglial processes containing high levels of Iba1 and actin - a postembedding immunogold study in the healthy rat brain. European Journal of Neuroscience 2030-2040.</td>
</tr>
</tbody>
</table>
Figure Legends

Figure 1 - BioLayout Express\(^3\)D generated transcript-to-transcript network graph of selected genes of interest.

A: The list of 492 genes of interest with an expression pattern indicative of disease association were organised into 2 main clusters within BioLayout Express\(^3\)D by MCL. The green cluster comprising 410 nodes was joined by 29,339 edges indicating a high degree of co-expression between genes. The smaller purple cluster comprised 67 nodes and 1453 edges. B: The disease associated gene expression signatures of both clusters, displayed as a mean expression profile for each strain, revealed an up-regulation at approx. 50% of incubation period. The profile was similar for all genes in all mouse/prion combinations. The smaller purple cluster was expressed highest in BL6 strains resulting in the formation of a separate cluster. Error bars equate to ± SE. Grey triangles on X-axis indicate the incubation period between the point of inoculation to cull, some mouse/TSE strains leading to pathology and death faster than others.

Figure 2 - Cross reference of the 492 disease associated genes with co-normalised external datasets within BioLayout Express\(^3\)D.

Within BioLayout Express\(^3\)D each gene of interest was classed and coloured as a specific cell type. Note how the previously determined MCL clusters are both dominated by myeloid derived genes (green). Genes associated with myeloid were divided into two groups based on sole association with myeloid cell types or in which sole origin could not be determined. Sole myeloid origin comprised 318 genes or 64% of the gene set. A total of 146 genes were associated with multiple cell types found within the CNS. Here a myeloid component was
still observed as strongly associated with the group. Genes assigned to astrocytes, oligodendrocytes and neurons were each represented by <20 genes.

Figure 3 - PrP Deposition and Microglia Activation Assessed by immunohistochemistry

Microglia activation was observed in the same areas as PrP deposition. A/B: Earliest accumulation of PrP (6H4) is at 150 dpi in the Medulla. Microglia can be seen C/D: as accumulating in the same areas of deposition. E/F: Normal Microglia in the thalamus and medulla respectively of mice challenged with normal brain demonstrate a ramified appearance and greater separation at ~ 50 µm. All images representative. Scale bars equate to 100 µm.

Figure 4 - Software determined quantification of EGFP expressing microglia in 79A infected BALB/c<sup>fms-EGFP/</sup><sup>-</sup> mice.

A: Quantification of regional microglia cell number in BALB/c<sup>fms-EGFP/</sup><sup>-</sup> mice following i.p. challenge with 79A at 100, 150 and 200 dpi. EGFP expressing cells were counting using ImageJ particle analysis function on x10 magnification 25µm Z-stack compiled images each comprising 50 optical slices. Microglia density increases in the medulla by ~ 50% at 150 dpi whereupon numbers remain constant in this region as PrP deposition spreads anteriorly. By 200 dpi microglia density in the thalamus has increased by ~ 100%. B: EGFP expressing microglia in the thalamus of BALB/c<sup>fms-EGFP/</sup><sup>-</sup> mice following i.p. challenge with 79A at 150 and 200 dpi. No difference in the number of EGFP expressing cells was observed in the
thalamus until 200 dpi when a concentration of reactive microglia spaced less than 25 µm was observed. Before 200 dpi microglia were observed in all animals as spaced at 50 - 100 µm and adopt a normal ramified morphology. Scale bars equate to 200 µm. Inset scale bars equate to 20 µm. C: At 200 dpi, microglia present with an engorged central body and shortened processes conferring a significant reduction in radius. D: Euclidean distance mapping affords a highly sensitive quantification of cell complexity encompassing both cell body size and process branching. The reduction in cell radius at 200 dpi is reflected in a mean Euclidean distance increase of 1 µm. Distance mapping also detailed a slightly less complex cell type in the NBr animals. E: High Resolution image analysis of microglia density per 0.05 mm² in the thalamus at 200 dpi revealed an increase of ~100%. † Comprises mean for all NBr inoculated BALB/cFms-EGFP/-mice at all serial investigation time points. # Mean statistical value determined using t-Test assuming variances determined by f-Test. NS = Not Significant. A, C-E: error bars equate to ± SE.

Figure 5 - Purity of isolated microglia was confirmed to be high and extracted RNA was confirmed to be of workable quality.

A: FACS sample analysis of CD11b microbead purified microglia stained with, and positive for, CD11b-PE & CD45-APC demonstrate a high purity. B: Isotope control and C: negative control show no non-specific binding or auto-fluorescence respectively. D: Cell viability was confirmed using SYTOX® live-dead stain. Inset: Isolated cells are EGFP positive. E: Plot of the mean expression profile of twenty genes known to be expressed in a cell-specific manner. The first five are known microglial expressed genes, the remainder are expressed in other brain cell types. This demonstrates that the expression of non-microglia genes in isolated
microglial populations is negligible, suggesting a relatively pure microglial population. Error bars equate to ± SE.

**Figure 6 - BioLayout Express<sup>3D</sup> analysis of isolated microglia gene expression.**

A: Average expression profile of the 2 large clusters produced within BioLayout Express<sup>3D</sup> by the 741 genes that demonstrate a differential expression in response to disease. All genes yielded an increase in expression with a large escalation at 200 dpi in 79A infected mice. Error bars equate to ± SE. B: Global microarray sample-to-sample transposed BioLayout Express<sup>3D</sup> graph of the 741 identified genes of interest. Prion infected and uninfected pre-200 dpi arrays are highly correlated and organised into one component. Displaying high inter-correlation but lower correlation with the rest of the population are the arrays for the 200 dpi infected group. Note: nodes have been coloured only for clarity and are not indicative of MCL clustering.

**Figure 7 - Ontological analysis of the microglia activation signature within the 741 genes of interest.**

A: GO enrichment terms determined from the identified 741 differentially expressed genes using FuncAssociate 2.0 revealed protein translation, respiration, cellular stress and components of the myeloid immune system to be significantly represented. All terms have a P-value of considerably less than 0.001. B: Regulated disease-associated genes allocated by function. Using the Ensembl Biomart database the majority of the regulated genes were ascribed to metabolism and homeostasis. Genes associated with immune system, for which differentiation has been included, comprise only a fifth. This highlights the power of a signal
cell isolation in correctly determining the association of metabolic genes with a specific cell
type. C: Expression of inflammatory cytokines and transcription factors associated with the
regulation of activation phenotype of microglia. Strong increase in expression of Tnfa and
Il1b, but not cytokines associated with recruitment and escalation toward acquired
immunity imply a disease-specific signature. D: Nominal and unchanged expression of
Tgfb1 is matched by a lack of expression of downstream transcripts mediated by TGFB1
activity. C-D error bars equate to ± SE.

Figure 8 - Genes of interest associated with metabolism and homeostasis.

A considerable number of genes with an increase in expression are associated with protein
translation and processing. The increased metabolic load is reflected in the increase in
expression of genes associated with energy production.

Figure 9 - Genes of interest associated with immune activation and cell-to-cell signalling.

Genes have been grouped by both function and cellular location. The signature is one of
robust pro-inflammatory innate immune activation.
Figure 1

A

B

Relative Expression

Mouse/Prion Strain Combination

FVBPrnp00
RML

B6I1
RML

BL6
301V

BL6
RML

FVBNCr
RML

B4053
RML

51 Weeks 9 Culls
56 Weeks 14 Culls
52 Weeks 11 Culls
41 Weeks 11 Culls
18 Weeks 9 Culls
23 Weeks 12 Culls
22 Weeks 11 Culls
8 Weeks 8 Culls

Mouse/Prion Strain Combination
Figure 2

The figure depicts the relative expression of different cell types: Myeloid, Neuron, Astrocyte, and Oligodendrocyte. The y-axis represents the relative expression values ranging from 0 to 8000. The x-axis shows the cell types.

- **Myeloid** is represented with green dots and bars, showing a peak at around 64%.
- **Neuron** is depicted with blue dots and bars, showing a peak at 1%.
- **Astrocyte** is marked with red dots and bars, showing a peak at 4%.
- **Oligodendrocyte** is indicated with orange dots and bars, showing a peak at 1%.

A pie chart summarizes the distribution of cell types, with Myeloid at 64%, Oligodendrocyte at 1%, Astrocyte at 4%, and Neuron at 1%, labeled "Generic."
Figure 3
**Figure 4**

**A**

- Graph showing the number of EGFP expressing microglia in different brain regions (Thalamus, Medulla, Dentate gyrus, Cerebellum) across different dpi (100, 150, 200, 250, 300, 350, 400)
- Statistical significance indicated by P = 0.020 and P = 0.029

**B**

- Images showing thalamic microglia expression across different dpi (150, 200)
- Scale bars shown for each image

**C**

- Graph showing thalamic microglia radius (µm) with significance indicated by P = 3.5 x 10^-12
- NS (non-significant)

**D**

- Graph showing thalamic microglia mean EDM (µm) with significance indicated by P = 4.5 x 10^-19
- P = 0.0015

**E**

- Graph showing thalamic microglia radius (µm) with significance indicated by P = 3.8 x 10^-14
- NS
Figure 5

A

B

C

D

E

Mean Relative Expression
Gene & Cell Origin
NS
† P = 0.0012
Microglia
Astrocyte
Neuron
Oligodendrocyte

Gene & Cell Origin
Figure 6
### A

<table>
<thead>
<tr>
<th>GO Ontological Annotation</th>
<th>GO ID</th>
<th>P-value</th>
<th>Gene No.</th>
<th>% Within Dataset</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protein Translation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• ribosome</td>
<td>GO:0005840</td>
<td>6.37 x 10^{-54}</td>
<td>72</td>
<td>9.72</td>
</tr>
<tr>
<td>• translation</td>
<td>GO:0006412</td>
<td>3.52 x 10^{-26}</td>
<td>67</td>
<td>9.04</td>
</tr>
<tr>
<td>• ribosome biogenesis</td>
<td>GO:0042254</td>
<td>2.70 x 10^{-12}</td>
<td>27</td>
<td>3.64</td>
</tr>
<tr>
<td>• endoplasmic reticulum</td>
<td>GO:0005783</td>
<td>1.11 x 10^{-05}</td>
<td>68</td>
<td>9.18</td>
</tr>
<tr>
<td>Energy Production</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• mitochondrion</td>
<td>GO:0005739</td>
<td>1.10 x 10^{-13}</td>
<td>111</td>
<td>14.98</td>
</tr>
<tr>
<td>• generation of</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>precursor metabolites</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>and energy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• respiratory chain</td>
<td>GO:0070469</td>
<td>1.92 x 10^{-13}</td>
<td>19</td>
<td>2.56</td>
</tr>
<tr>
<td>Immune Response</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• lysosome</td>
<td>GO:0005764</td>
<td>1.55 x 10^{-12}</td>
<td>42</td>
<td>5.67</td>
</tr>
<tr>
<td>• regulation of cytokine</td>
<td>GO:0001817</td>
<td>1.47 x 10^{-09}</td>
<td>38</td>
<td>5.13</td>
</tr>
<tr>
<td>production</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• chemokine receptor</td>
<td>GO:0042379</td>
<td>2.20 x 10^{-09}</td>
<td>13</td>
<td>1.75</td>
</tr>
<tr>
<td>binding</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• regulation of</td>
<td>GO:0040012</td>
<td>1.03 x 10^{-07}</td>
<td>41</td>
<td>5.53</td>
</tr>
<tr>
<td>locomotion</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• endosome</td>
<td>GO:0005768</td>
<td>6.35 x 10^{-07}</td>
<td>41</td>
<td>5.53</td>
</tr>
<tr>
<td>• cell proliferation</td>
<td>GO:0008283</td>
<td>3.00 x 10^{-06}</td>
<td>78</td>
<td>10.53</td>
</tr>
<tr>
<td>• I-kappα kinase/NF-</td>
<td>GO:007249</td>
<td>8.03 x 10^{-06}</td>
<td>19</td>
<td>2.56</td>
</tr>
<tr>
<td>kappα cascade</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• innate immune response</td>
<td>GO:0002758</td>
<td>1.38 x 10^{-05}</td>
<td>12</td>
<td>1.62</td>
</tr>
<tr>
<td>activating signal</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>transduction</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interferon Response</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• response to interferon-</td>
<td>GO:0034341</td>
<td>1.32 x 10^{-07}</td>
<td>12</td>
<td>1.62</td>
</tr>
<tr>
<td>gamma</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• response to interferon-</td>
<td>GO:0035456</td>
<td>1.60 x 10^{-07}</td>
<td>9</td>
<td>1.21</td>
</tr>
<tr>
<td>beta</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• response to type I</td>
<td>GO:0034340</td>
<td>8.99 x 10^{-07}</td>
<td>7</td>
<td>0.94</td>
</tr>
<tr>
<td>interferon</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cell Stress</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• response to stress</td>
<td>GO:0006950</td>
<td>2.53 x 10^{-13}</td>
<td>138</td>
<td>18.62</td>
</tr>
<tr>
<td>• apoptotic process</td>
<td>GO:0006915</td>
<td>5.05 x 10^{-07}</td>
<td>82</td>
<td>11.07</td>
</tr>
<tr>
<td>• response to wound</td>
<td>GO:0009611</td>
<td>3.06 x 10^{-06}</td>
<td>45</td>
<td>6.07</td>
</tr>
</tbody>
</table>

### B

- Immune Function: 21%
- Metabolism/Homeostasis: 62%
- Apoptosis: 4%
- Mitosis: 4%
- Apoptotic process
- Response to stress
- Response to wounding
- Translation
- Ribosome
- Endoplasmic reticulum
- Mitochondrion
- Generation of precursor metabolites and energy
- Respiratory chain
- Lysosome
- Regulation of cytokine production
- Chemokine receptor binding
- Regulation of locomotion

### C

- TGF-β1
- IFN-γ
- IL-10
- TNF-α
- STAT3
- NF-κB

### D

- Array Group Avg. Expression
**Figure 8**

**DNA Binding/Repair**

120004'i1306k, Aphi3, Dek, Dmrtc1c, Dnmt3a, Dscsl1, E4f3, Fam50a, Min39a, Min62-2b, Nono, Rps27, Rap14, Pgap1, Rif, Sap30, Trip12, Uba52, Utp3, Xrn2, Zbp1, Zcchc17

**Transcription**

Bcs2, Chrc1, Cicc, Cops5, Crefb, Cux1, Ddx1, Drap1, Ebnal1bp2, Epsr, Exoc9, Fcfl, Hmnr3, Ipso, Mbd2, Mina, Mdbk, Naca, Npat, Phf11d, Prpf6, Pitbp1, Pus3, Rbm42, Rpp38, Rtc8, Scadi1, Smn1, Serd3, Snfl4, Snord38a, Snrpe, Snrpf, Syncp, Synx2, Taf10, Taf51, Tat62, Tce2b, Trim30a, Utp11i, Utp14a, Yaf2, Znht1, Znmd1

**Translation**

Eef1a2, Eif1a, Eif2e2, Eif3e, Eif3h, Eif3k, Eif3l, Eif4f, Etf1, Fau, Gm6251, Lsm2, Mrp132, Mrp134, Mrp136, Mrfr, Narf1, Oas1g, Oas2r, Opi10a, Opfl1, Opfl3, Opfl13a, Opfl14, Opfl18a, Opfl19, Opfl21, Opfl22, Opfl21, Opfl26, Opfl27, Opfl28, Rp8, Rp101, Rp112, Rp132, Rp135, Rp135a, Rp136, Rp136a, Rp136al, Rp137, Rp137a, Rp138, Rp139, Rp139l, Rp140, Rp141, Rp156, Rp17, Rp18, Rp1p0, Rps10, Rps11, Rps12, Rps14, Rps15a-p56, Rps16, Rps17, Rps18, Rps19, Rps20, Rps20, Rps23, Rps25, Rps26, Rps27a, Rps29, Rps3, Rps3a, Rps4x, Rps5, Rps6, Rps7, Rps8, Sart3, Scc3b, Scc63

**Lipid Processing (membrane)**

Abca1, Abcb6, Abct10, Ama3, Aplp2, Apob, Apobec1, Apoc1, Apoe, Ch25h, Chchd3, Fam167b, Gde1, Ghp, Lrapap1, Mr1, Osbp8, Pcyt1a, Peci, Plc3, Pln2, Ppap2a, Ppfrn, Ptg5, Ppida2, Spp1, Srr5a3, Ttc1

**Energy Production**

270003k'1306k, Acad8, Acp1, Atp5e, Atp5h, Atp5k, Atp5s, Atp5v, Cc231, Cox6a1, Cox6a2, Cox6b1, Cox7a1, Cox8a, Cybb, Cysc, Cyp4a3, Fd1x, Gink5, Gm10136, Gpelp1, Hgd1a, Hgd2a, Hsd17b11, Idh1, Idh2, Ildh, Ndua1, Ndufa2, Ndufa3, Ndufa4, Ndufa6, Ndufb11, Ndufl2, Nduv3, Porda, Rom1c, Scl25a4, Surfl, Tmx3, Tomm7, Tndc5, Uqcr10, Uqcrb, Uqcrh, Usmg5, Vat1, Xdh

**General Metabolism**

1700021f065rk, 1810037i17rk, 2010107e04rk, Akr1a4, Alas1, Ati2, Azin1, Bhhb9, Casd1, Dpy19h4, Ennp1, Erbb2ip, Evi2a, Exf9, Fam165b, Fam174a, Fund2c, Gm10063, Impad1, Lsm11a, Ly4e, Mce2, Mrp139, Mrp152, Mrp33, Mrp39, Naa20, Nal50, Nd1, Ndufa8, Ndufb2, Ndufb5, Oectl, Pde4dip, Pgam1, Ppmn1, Smpdl3a, Surf4, Tor3a, Vkorcl, Wbp5,

**Protein Processing (Inc. Proteasome)**

Cndp2, Cpd, Cued2, Cu4b, Der13, Dnajb14, Erclec1, Fxww4, Ig5l, Mmp12, Nedd8, Pfen1, Pfen5, Prma7, Pumb1, Pumb2, Pumb3, Pumb4, Pumb6, Pumb8, Pume1, Putra, Rbx1, Sfrnm1, Spcs1, St14, Sti5a6, Tce6, Tcl1, Utb5,

**Protein Transport (Inc. Vesicular)**

Apl3a1, Arkip5p, Bst2, Cct2, Chmp3b, Chmp7, Exoc2, Golin4, Golph3, Gosr2, Mrfs1, Mrgpt2, Mtrm2, Mykl6, Nipsnap3b, Nup98, Pleckha3, Rab1b, Rap2a, Rap2b, Rasgefl1b, Rer1, Rtp4, Scc3a2, Sic13a6, Sic13a6, Sic7a11, Snap29, Sna17, Snx1, Snx2, Srp14, Srp72, Tbc1d22a, Tmed9, Vps28, Vps29, Vte1b,

**Carbohydrate Metabolism**

Chat1, Chat11, Chat2, Gaitn6, Gaitn7, Gent2, Gftp1, Gmds, Gnpd1a, Gnpab, Gypg, Mfrb3, Mrk1, Pgk1, Pgl, Pigu, Pkra1a, Tpi1,
Figure 9

Mitosis/Proliferation
Anapc13, Ankara, Bola2, Ccny, Cd180, Cenpc1, Cenpo, Copt35, Cetn3, Cip23, Cks1b, Dna2, Ecd, Efd1, Gnl3, Har1, Hprt, Impdh2, Mcm3, Mcm6, Mtap4, Npm1, Nus1, Ogrf, Ott, Ppplcc, Ranbp1, Rcc2, Rhoc, Rnaseh2b, Sipri1, Sinf5, Sais6, Sscar1, Top2a

Cytokines & Chemokines
Cc14, Cc15, Cc28, Cc9, Cci2, Csfl, Cxcl11, Cxcl13, Cxcl14, Cxcl16, Cxcl9, Hebp1, Il12b, Il1b, Tnf

Synapse / Axon Function
Alcam, Apbb2, App, Atnm10, Cadm1, Caprin1, Got1, Grasp, Grin1a, Hga2, Kann2, Krtcap2, Lgal1, Neu1, Nrp1, Pknb2, Sdc3, Sulf2, Syngr1

Pro-inflammatory Signalling
1700112G06Rik, 5430435G22Rik, Aggf1, Cd14, Cd200d, Cd48, Cd84, Cd86, Clec37, Clec5a, Clec7a, Colec12, Csf2rb2, Cxcl10, Cxcr4, Fapyb5, Fam20c, Fgr4, Fth1, H51, Hf32, Gadd45a, Gadd45g, Gem, Gig1r, Gng5, Grpr84, H2a, H2-d1, H2-g10, H2-K1, H2-Q7, H2-T10, H2-T9, Hctt, Hucz, Ikbke, Il100112016Rik, Ild2, Ifi20b, Il30, Il64, Il11, Ifi1, Ifi12, Ifi13, Ifi13m, lgbp1, ilkbe, il2rg, Irf1, Irf7, Ilar, Lasp1, Lpl2, Ly6a, ly9, Map3k7, Map3k8, Mif, Nkap, Nmi, olai1, Parp9, Ptgcr4, Rob1d3, Sdcph, Sfamf9, St1, Stat1, Tappb, Tir1, Tlr2, Tmem9b, Tnflsp2, Tendif7

Anti-inflammatory Signalling
Atp6ap2, Axl, Bag1, Bcl2a1a, Bcl2a1b, Bcl2a1c, Bcl2a1d, Cd274, Cd300f, Cds2, Cds2, Cds3, Cds9, Commd1, Conk2b, Ct7, Fgl2, Hgf, Hnt1, H2o4, H2o6b, Igal, Kf910, Libb4, Mir1, Naip2, Nfkb1, Nfkbib, Nfkbie, Rasad2, Serpine2, Sifmb, Spop1, Spp1, Tank, Timp2, Tnflsp3, Tpt1, Ubn1, Uspl5, Zc3h12a

Lyosome Function
081003106Rik, Arcre2, Asah1, Atp6v0e, Atp6v1a, Atp6v1q1, Biloc1s2, Creg1, Cibs, Cnts, Ctsa, Ctsb, Ctsd, Cth, Ctsl, Ctsv, Dpp7, Drem2, Fucal, Furin, Gaa, Galc, Gba, Glu, Gbi, Gm2a, Gns, Gsto1, Gusb, Irgm1, Lamp1, Lamp2, Lytl, Lyz2, Npc2, Rab12, Riplp2, Rnf128, Rnf13, Rragc, Septm1

Cytoskeleton
Aregap24, Arli2, Arp31b, Arp51i, Baiap2, Bst2, Capg, Cfl1, Coro1c, Dctn6, Diap2, Dtnbp1, Ecad2, Ezr, F2r, Fina, Fmr1, Gas131, Gpr65, Kif1a, Myo1e, Myo5a, Nexn, Nuak2, Plekh2b, Sdc4, Tbc1, Tmsb10, Tpm4, Ttc31b, Tubb2a, Vim

Complement
C4b, C3ar1

Cell Migration & Recruitment
Ccd23, Ctnnb1, Hspsb11, Hga1, Lgal1, Lgal3b, Lgal3bp, Lox, Lpl, Mfap1a, Nps1, Npt1, Nptm, Plau, Plaur, Psutn, Vcam1

Redox Stress
Adh5, Aldoa, Atox1, Cn8, Cops6, Coq7, Cox4i1, Cstb, Gpx4, Hif1a, Hspa1, Hsp27, Hsp272a, Mapkapk2, Myovu2, Nef1, Plekh1a, Ppp1r15b, Pnkd1, Prkd1, Slc002, Selm, Serpl, Tacc3, Vac14

Apoptosis (Pro & Anti)
11100070b9Rik, Adar, Casp4, Cita2a, Dusp2, Eif2ak2, Fam32a, Fnip2, Gabarapl1, Gsthm, Ngfapl1, Niac1, Pobd5, Pobd6, Rasd4, Sp100, Sk3, Tmem69